Quantity of qualified patients: CDEC mentioned the uncertainty in the quantity of people with moderately significant to intense hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some sufferers that are classified as having gentle or reasonable disease could have a severe bleeding phenotype, https://hemgenix06048.shotblogs.com/not-known-details-about-hemgenix-49753460